Drug Trial Radar · NCT04032067
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
Last checked: Nov 19, 2026Latest source record: Aug 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
423
Actual
Start
Oct 30, 2019
Primary completion
Mar 17, 2022
Study completion Mar 17, 2022
Sponsor
- Lead sponsor
- GemVax & KaelIndustry
- Sponsor type
- Industry
- First posted
- Jul 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered as a treatment for Benign prostate hyperplasia(BPH). The investigational drug, GV1001, was first developed as a cancer vaccine for use as active immunotherapy of cancer forms expressing telomerase (eg, pancreatic cancer, prostate cancer, etc.). Subsequently, it was found that GV1001 showed efficacy in alleviating BPH symptoms during in vivo studies by reducing the size of the prostate gland. Based on the result, the effectiveness of GV1001 as a treatment for BPH has been assessed in experimental animals that are designed to develop BPH. It is considered that GV1001 acts to alleviate BPH and the results obtained from previous phase II study indicate that GV1001 may provide potential beneficial effects in BPH patients. So this study is to verify the efficacy and safety of GV1001 on BPH population, large-scale clinical study than phase II.
Conditions
- Benign Prostatic Hyperplasia (BPH)
Interventions
GV1001 placeboDrug
0.9 % Normal Saline
Proscar placeboDrug
PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in International Prostate Symptom Score(IPSS)Time frame: Week 24
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Hallym University Medical Center
Anyang, South Korea
Inje University Busan Paik Hospital
Busan, South Korea
Samsung Changwon Medical Center
Changwon, South Korea
Soonchunhyang University Hospital
Cheonan, South Korea
Daegu Catholic University Medical Center
Daegu, South Korea
Keimyung University Dongsan Medical Center
Daegu, South Korea
Kyungpook National University Chilgok Hospital
Daegu, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Dongguk University Ilsan Hospital
Ilsan, South Korea
Jeonbuk National University Hospital
Jeonju, South Korea
Chungbuk National University Hospital
Jungbuk, South Korea
Chonnam National University Hospital
Jungnam, South Korea
Asan Medical Center
Seoul, South Korea
Chung-ang University Hospital
Seoul, South Korea
Eulji General Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Severance Hospital
Seoul, South Korea
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, South Korea
Pusan National University Yangsan Hospital
Yangsan, South Korea
Hanyang University Guri Hospital
Guri-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Dongguk University Gyeongju Hospital
Gyeongju, Gyeongsangbuk-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.